Cardiovascular Effects of Non-Cardiovascular Drugs — MCQs
A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?
Drug that does not cause cardiac depression:
Identify the correct match, regarding the drug and its adverse effect.
Which of the following drugs, when given with erythromycin, can cause QT prolongation and Torsades de Pointes?
What is a potential risk associated with the use of thiazolidinediones in the treatment of type 2 diabetes?
A mother reports that her daughter ingested a substance in an unknown dose. The girl presents with hypertension, tachycardia, mydriasis, and hyperthermia. What is the most likely substance?
The cardiovascular side effects of Dexmedetomidine are as follows:
Which of the following drugs has the LEAST cardiac side effects when used for treating an acute attack of asthma in a cardiovascular patient?
For a patient diagnosed with dyslipidemia characterized by elevated LDL cholesterol levels, what is the most appropriate treatment?
Which statin is considered most potent based on mg-to-mg LDL reduction capability?
Cardiovascular Effects of Non-Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs
Question 1: A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?
- A. Hepatotoxicity
- B. Pulmonary fibrosis
- C. Fluid retention (Correct Answer)
- D. Hypokalemia
Explanation: ***Fluid retention***- **Pioglitazone**, a thiazolidinedione (TZD), commonly causes **fluid retention** or edema [1].- This fluid retention can **exacerbate heart failure** symptoms and lead to cardiac decompensation, especially in patients with pre-existing heart conditions [1].*Hepatotoxicity*- While TZDs like pioglitazone have been associated with **liver dysfunction** in some cases, significant hepatotoxicity is rare and usually not the primary concern or most common serious side effect [1].- **Regular monitoring of liver enzymes** is recommended, but fluid retention leading to heart failure exacerbation is a more immediate and severe risk in this patient profile.*Pulmonary fibrosis*- **Pulmonary fibrosis** is not a known or common complication directly associated with pioglitazone use.- This complication is typically linked to other medications or systemic diseases.*Hypokalemia*- **Hypokalemia**, or low potassium levels, is generally not a direct side effect of pioglitazone.- Electrolyte imbalances associated with heart failure or diuretic use, rather than pioglitazone itself, are more likely causes of hypokalemia.
Question 2: Drug that does not cause cardiac depression:
- A. Thiopentone
- B. Ketamine
- C. Propofol
- D. Etomidate (Correct Answer)
Explanation: ***Etomidate*** - Etomidate is known for its **cardiovascular stability**, making it a preferred induction agent in patients with **compromised cardiac function**. - It maintains **myocardial contractility** and does not typically cause a significant drop in blood pressure. *Thiopentone* - Thiopentone causes **dose-dependent myocardial depression** and peripheral vasodilation. - This can lead to a significant **decrease in blood pressure** and cardiac output, especially in hypovolemic patients. *Propofol* - Propofol is a potent **vasodilator** and can cause significant **myocardial depression**, leading to hypotension. - Its cardiovascular effects are often more pronounced than those of other induction agents, necessitating careful titration. *Ketamine* - Ketamine causes indirect cardiovascular stimulation (due to **sympathetic nervous system activation**), but direct myocardial depression. - While it often increases heart rate and blood pressure, this is a compensatory mechanism and its direct effect on the myocardium is depressant.
Question 3: Identify the correct match, regarding the drug and its adverse effect.
- A. Aliskiren - hypokalemia
- B. Hydralazine - heart failure
- C. Atenolol - hemolytic anemia
- D. Verapamil - constipation (Correct Answer)
Explanation: ***Verapamil - Constipation*** - **Verapamil**, a **non-dihydropyridine calcium channel blocker**, frequently causes constipation due to its effect on smooth muscle in the gastrointestinal tract, leading to **decreased intestinal motility**. - This adverse effect is common and often dose-dependent, making it a significant consideration in patient management. *Aliskiren - hypokalemia* - **Aliskiren**, a **direct renin inhibitor**, can cause **hyperkalemia** by reducing angiotensin II levels, which normally stimulate aldosterone secretion. - It does not typically cause hypokalemia; rather, potassium-sparing effects are often observed. *Hydralazine - heart failure* - **Hydralazine** is a **vasodilator** used to treat hypertension and **heart failure** with reduced ejection fraction by reducing afterload. - It does not cause heart failure; instead, it is often prescribed to improve cardiac function in patients with heart failure. *Atenolol - hemolytic anemia* - **Atenolol** is a **beta-blocker** primarily used for hypertension, angina, and arrhythmias. - **Hemolytic anemia** is a rare adverse effect associated with certain drugs, but it is not a known or common side effect of atenolol.
Question 4: Which of the following drugs, when given with erythromycin, can cause QT prolongation and Torsades de Pointes?
- A. Astemizole (Correct Answer)
- B. Cetirizine
- C. Loratadine
- D. Promethazine
- E. Fexofenadine
Explanation: ***Astemizole*** - **Astemizole** is a second-generation antihistamine that undergoes extensive metabolism by the **CYP3A4 enzyme**. - Concomitant use with **erythromycin**, a potent **CYP3A4 inhibitor**, significantly increases astemizole plasma concentrations, leading to **QT prolongation** and an elevated risk of **Torsades de Pointes**. *Cetirizine* - **Cetirizine** is another second-generation antihistamine that is primarily eliminated via **renal excretion** and does not undergo significant CYP450 metabolism. - Therefore, its co-administration with **erythromycin** does not typically lead to clinically significant drug interactions impacting cardiac repolarization. *Fexofenadine* - **Fexofenadine** is a second-generation antihistamine and active metabolite of terfenadine that is primarily eliminated via **biliary excretion** and has minimal hepatic metabolism. - While it is a substrate of **P-glycoprotein** (which can be inhibited by erythromycin), fexofenadine has a much safer cardiac profile and does not typically cause **QT prolongation** even with CYP3A4 inhibitors. *Loratadine* - **Loratadine** is a second-generation antihistamine that is metabolized by **CYP2D6** and **CYP3A4**, but its active metabolite, desloratadine, has a lower propensity for QT prolongation. - While erythromycin is a CYP3A4 inhibitor, the risk of **QT prolongation** with **loratadine** is generally considered much lower than with astemizole, even with concurrent use. *Promethazine* - **Promethazine** is a first-generation antihistamine and phenothiazine derivative that primarily acts as a **dopamine D2 receptor antagonist**. - While it can cause **QT prolongation** on its own at high doses, its metabolism is complex and not predominantly dependent on **CYP3A4** to the extent that interaction with **erythromycin** poses the same severe risk as with astemizole.
Question 5: What is a potential risk associated with the use of thiazolidinediones in the treatment of type 2 diabetes?
- A. Heart failure (Correct Answer)
- B. Pulmonary fibrosis
- C. Myocarditis
- D. Renal dysfunction
Explanation: ***Heart failure*** - Thiazolidinediones (TZDs), such as **pioglitazone** and **rosiglitazone**, can cause **fluid retention** and **volume expansion**, which may precipitate or worsen congestive heart failure. - This risk is higher in patients with pre-existing cardiac conditions and is a significant concern for these drugs. *Pulmonary fibrosis* - **Pulmonary fibrosis** is not a known or common adverse effect associated with thiazolidinedione use. - This condition is typically linked to certain other medications (e.g., **amiodarone**, **methotrexate**) or systemic diseases. *Myocarditis* - **Myocarditis**, inflammation of the heart muscle, is not a recognized side effect of thiazolidinediones. - Myocarditis is more commonly caused by viral infections, autoimmune diseases, or hypersensitivity reactions to certain drugs, but not TZDs. *Renal dysfunction* - While TZDs can cause fluid retention, they do not directly cause **renal dysfunction** or damage the kidneys. - In fact, some studies suggest they may have renoprotective effects due to reduced proteinuria, although fluid balance needs careful monitoring in patients with impaired renal function.
Question 6: A mother reports that her daughter ingested a substance in an unknown dose. The girl presents with hypertension, tachycardia, mydriasis, and hyperthermia. What is the most likely substance?
- A. Heroin
- B. Morphine
- C. Cocaine (Correct Answer)
- D. Chlorpheniramine
- E. Organophosphate
Explanation: ***Cocaine*** - The presented symptoms of **hypertension, tachycardia, mydriasis, and hyperthermia** are characteristic of a **sympathomimetic toxidrome**, frequently caused by cocaine overdose. - Cocaine acts as a **norepinephrine-dopamine-serotonin reuptake inhibitor**, leading to excessive stimulation of the central and peripheral nervous systems. *Heroin* - Heroin is an **opioid**, and overdose generally presents with **respiratory depression, bradycardia, miosis (pinpoint pupils)**, and hypotension, which are contrary to the patient's symptoms. - Patients typically exhibit central nervous system **depression**, rather than the hyperactive state seen here. *Morphine* - Similar to heroin, morphine is an **opioid** and causes symptoms like **respiratory depression, bradycardia, miosis**, and hypotension. - These effects are the opposite of the **sympathomimetic** signs observed in the patient. *Chlorpheniramine* - Chlorpheniramine is an **antihistamine** with significant **anticholinergic effects**. An overdose might cause **mydriasis and tachycardia**, but not typically severe hypertension or hyperthermia as the primary features. - Other anticholinergic signs such as **dry mucous membranes, urinary retention, and altered mental status (delirium)** would also be expected. *Organophosphate* - Organophosphate poisoning causes a **cholinergic toxidrome** due to **acetylcholinesterase inhibition**, resulting in excessive cholinergic stimulation. - Classic presentation includes **SLUDGE syndrome** (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) along with **miosis (pinpoint pupils), bradycardia, bronchospasm**, and muscle fasciculations. - These findings are the **opposite** of the sympathomimetic signs seen in this patient.
Question 7: The cardiovascular side effects of Dexmedetomidine are as follows:
- A. Hypertension and Tachycardia
- B. Hypertension and Bradycardia
- C. Hypotension and Bradycardia (Correct Answer)
- D. Hypotension and Tachycardia
Explanation: ***Hypotension and Bradycardia*** - **Dexmedetomidine** is an **alpha-2 adrenergic agonist** that causes a dose-dependent decrease in heart rate (bradycardia) and blood pressure (hypotension) due to reduced sympathetic outflow. - The initial hypertensive effect seen with rapid IV administration is usually transient and followed by sustained hypotension. *Hypertension and Tachycardia* - This combination is not typical for **dexmedetomidine**, which primarily exerts its effects by centrally reducing sympathetic tone, leading to lowered heart rate and blood pressure. - **Tachycardia** is a rare and usually reflex-mediated response if severe hypotension occurs, but it's not a primary effect. *Hypertension and Bradycardia* - While an initial, transient **hypertension** can occur with rapid **dexmedetomidine** infusion due to peripheral alpha-2 stimulation, this is not its predominant long-term cardiovascular effect. - The sustained effect is usually **hypotension**, not hypertension, making this option incorrect as a primary side effect. *Hypotension and Tachycardia* - Although **hypotension** is a common side effect of **dexmedetomidine**, **tachycardia** is generally not. - The drug mainly causes a reduction in heart rate (**bradycardia**) as part of its central sympatholytic action.
Question 8: Which of the following drugs has the LEAST cardiac side effects when used for treating an acute attack of asthma in a cardiovascular patient?
- A. Salbutamol (short-acting beta-agonist)
- B. Terbutaline (short-acting beta-agonist)
- C. Ipratropium (short-acting anticholinergic) (Correct Answer)
- D. Formoterol (long-acting beta-agonist)
Explanation: ***Ipratropium (short-acting anticholinergic)*** - Ipratropium is a **bronchodilator** that acts as an **anticholinergic** via **M3 muscarinic receptor antagonism** in the airways. - It has **minimal systemic absorption** and produces **no direct cardiac stimulation**, making it the option with the least cardiovascular side effects. - While typically used as an **adjunct to beta-agonists** in acute asthma, it has the most favorable cardiac safety profile among bronchodilators. - Particularly useful in patients with **severe cardiovascular disease** where minimizing cardiac stimulation is crucial. *Salbutamol (short-acting beta-agonist)* - Salbutamol is a **selective beta-2 adrenergic agonist** and the first-line treatment for acute asthma. - Despite beta-2 selectivity, it can have **off-target effects on cardiac beta-1 receptors**, potentially causing tachycardia, palpitations, and increased myocardial oxygen demand. - At therapeutic doses, cardiac effects are usually mild and acceptable even in cardiovascular patients, but more pronounced than ipratropium. *Terbutaline (short-acting beta-agonist)* - Terbutaline is a **beta-2 agonist** with similar cardiac risk profile to salbutamol. - Can cause **tachycardia and arrhythmias** due to non-specific beta-adrenergic activation, particularly at higher doses or in sensitive patients. - Effective for acute bronchodilation but produces more cardiac stimulation than anticholinergics. *Formoterol (long-acting beta-agonist)* - Formoterol is a **long-acting beta-2 agonist (LABA)** with rapid onset but prolonged duration of action. - **Not recommended for acute asthma attacks** as monotherapy; LABAs are maintenance medications. - Has potential for significant **cardiac side effects** including palpitations, tremor, and arrhythmias due to prolonged beta-adrenergic stimulation. - Carries greater cardiovascular risk than short-acting agents due to extended systemic exposure.
Question 9: For a patient diagnosed with dyslipidemia characterized by elevated LDL cholesterol levels, what is the most appropriate treatment?
- A. Fibric acid derivatives
- B. Nicotinic acid
- C. Bile acid-binding resins
- D. Statins (Correct Answer)
Explanation: ***Statins*** - **Statins** are the frontline treatment for elevated **LDL cholesterol**, significantly reducing **cardiovascular risk** by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - They effectively **lower LDL levels** and have additional **pleiotropic effects** such as anti-inflammatory properties and plaque stabilization. *Fibric acid derivatives* - **Fibric acid derivatives** are primarily used to treat **hypertriglyceridemia** and can moderately increase HDL cholesterol, but they are less effective at lowering LDL cholesterol compared to statins. - They act by activating **PPAR-alpha**, leading to increased fatty acid oxidation and reduced triglyceride synthesis. *Nicotinic acid* - **Nicotinic acid** (niacin) is effective in **lowering triglycerides** and raising **HDL cholesterol**, but its impact on LDL cholesterol is less pronounced than statins, and it is associated with significant side effects like flushing. - It works by inhibiting hepatic VLDL synthesis and secretion, which indirectly impacts LDL formation. *Bile acid-binding resins* - **Bile acid-binding resins** reduce LDL cholesterol by binding bile acids in the intestine, leading to increased hepatic synthesis of bile acids from cholesterol and upregulation of LDL receptors. - While effective, they are generally less potent than statins and often cause **gastrointestinal side effects** such as constipation and bloating.
Question 10: Which statin is considered most potent based on mg-to-mg LDL reduction capability?
- A. Simvastatin
- B. Pravastatin
- C. Rosuvastatin (Correct Answer)
- D. Atorvastatin
Explanation: ***Rosuvastatin*** - **Rosuvastatin** is known for its high potency, achieving significant **LDL-C reduction** at relatively low doses. - It is often considered the most potent statin on a **milligram-to-milligram basis**. *Simvastatin* - **Simvastatin** is a moderate-intensity statin, not as potent as rosuvastatin or atorvastatin in reducing LDL-C. - While effective, it typically requires higher doses to achieve comparable **LDL-C reductions** seen with high-potency statins. *Pravastatin* - **Pravastatin** is a hydrophilic statin, generally considered to be of lower potency compared to other statins like rosuvastatin and atorvastatin. - It is often used in patients with **hepatic dysfunction** due to its different metabolic profile but offers less aggressive **LDL-C reduction**. *Atorvastatin* - **Atorvastatin** is a high-intensity statin, very effective in reducing LDL-C, and often used for aggressive lipid lowering. - While highly potent, **atorvastatin** is generally considered slightly less potent than **rosuvastatin** on a mg-to-mg basis, though both are used for high-intensity lipid therapy.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free